
Available to mentor

Dr. Joanna Spencer-Segal is a physician-scientist in the Department of Internal Medicine and the Michigan Neuroscience Institute. A neuroendocrinologist, she cares for patients with disorders of pituitary hormone function in the Multidisciplinary Pituitary Program. She runs a translational neuroendocrinology research program focused on improving our understanding of how circulating hormones control neural function and motivated behaviors, and the specific neural circuits that direct systemic endocrine function.
-
Postdoctoral Research Fellow, Molecular and Behavioral NeuroscienceUniversity of Michigan–Ann Arbor, Internal Medicine, 2017
-
Fellowship , Metabolism, Endocrinology and DiabetesUniversity of Michigan–Ann Arbor, Internal Medicine, 2016
-
Center MemberEisenberg Family Depression Center
The Spencer-Segal lab focuses on the neural circuits that govern emotional behaviors, both innately and in response to stress. Many of the regions of and circuits in the brain that play a role in emotional behavior also influence the stress response. Stress hormones also act directly on brain regions that influence mood and related behaviors. The Spencer-Segal laboratory is disentangling the neural circuits that direct stressor-specific neuroendocrine and behavioral responses.
Another area of research involves the neuroendocrinology of critical illness and sepsis. Critical illness is often fatal, and survivors face an uphill battle that frequently includes mental health challenges such as anxiety, depression, post-traumatic stress disorder, and cognitive dysfunction. Our lab is interested in understanding the role of the neuroendocrine stress response in short- and long-term critical illness outcomes, and using this knowledge to develop treatments to help patients. This research includes an interest in the influence of circulating hormones on memories formed during illness and their relationship to PTSD outcomes, the role of inflammatory mediators in anxiety- and depression-like emotional states in survivors, and mechanistic approaches to tackle the syndrome of glucocorticoid resistance during critical illness.
-
Samson SL, Donegan D, Geer EB, Gordon MB, Hamidi O, Huang W, Ioachimescu AG, Silverstein JM, Spencer-Segal JL, Tritos NA, Yuen KCJ. J Endocr Soc, 2025 Aug; 9 (8): bvaf103Journal ArticleManagement of Osilodrostat Therapy in Patients With Cushing's Syndrome: A Modified Delphi Consensus Panel.
DOI:10.1210/jendso/bvaf103 PMID: PMC12227144 -
Fleseriu M, Auchus RJ, Huang W, Spencer-Segal JL, Yuen KCJ, Dacus KC, Padgett J, Babler EK, Das AK, Campos C, Broder MS, Ioachimescu AG. Journal of the Endocrine Society, 2025 May 1; 9 (5):Journal ArticleOsilodrostat Treatment of Cushing Syndrome in Real-World Clinical Practice: Findings From the ILLUSTRATE study
DOI:10.1210/jendso/bvaf046 -
Spencer-Segal JL, Auchus RJ. J Clin Endocrinol Metab, 2025 Apr 2;Journal ArticleWake Up and Smell - the Cortisol?
DOI:10.1210/clinem/dgaf197 PMID: 40171920 -
2025 Feb 26;PresentationDiagnosis and management of prolactinomas in 2025: International consensus update
-
2025 Feb 26;PresentationAggressive pituitary tumors causing Cushing's disease
-
2025 Feb 26;PresentationMedical Treatment for Cushing's Disease
-
Spencer-Segal J. Psychoneuroendocrinology, 2025 Mar 7; 172: 107286Journal ArticleNeural regulation of stress responses via the ventral subiculum and BNST
DOI:10.1016/j.psyneuen.2025.107286 -
2025 Feb 26;PresentationGlucocorticoids and resilience
